
Tsung-Hao Liu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6650178/publications.pdf Version: 2024-02-01



Τευνις-Ηλο Ι.υ.

#	Article	IF	CITATIONS
1	Sorafenib Overcomes TRAIL Resistance of Hepatocellular Carcinoma Cells through the Inhibition of STAT3. Clinical Cancer Research, 2010, 16, 5189-5199.	7.0	155
2	CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene, 2010, 29, 6257-6266.	5.9	147
3	Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. Journal of Hepatology, 2010, 52, 88-95.	3.7	64
4	Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Liver Cancer, 2019, 8, 480-490.	7.7	57
5	Early alphaâ€foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma. Liver International, 2019, 39, 2184-2189.	3.9	55
6	Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment. Liver Cancer, 2019, 8, 110-120.	7.7	46
7	Modified CLIP with objective liver reserve assessment retains prognosis prediction for patients with advanced hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1336-1341.	2.8	25
8	Outcome of stage IV cancer patients receiving in-hospital cardiopulmonary resuscitation: a population-based cohort study. Scientific Reports, 2019, 9, 9478.	3.3	15
9	Novel systemic therapy for hepatocellular carcinoma. Hepatology International, 2020, 14, 638-651.	4.2	15
10	Revisiting Hepatic Artery Infusion Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2021, 22, 12880.	4.1	15
11	It takes two to tango: breakthrough advanced hepatocellular carcinoma treatment that combines anti-angiogenesis and immune checkpoint blockade. Journal of the Formosan Medical Association, 2021, 120, 1-4.	1.7	8
12	Considerations of heterogeneity in clinical trials for hepatocellular carcinoma. Expert Review of Gastroenterology and Hepatology, 2019, 13, 615-621.	3.0	5
13	Successful Hepatic Arterial Infusion of Chemotherapy in a Patient with Advanced Hepatocellular Carcinoma and Impending Liver Failure. Liver Cancer, 2018, 7, 205-208.	7.7	4
14	Minimum cycle bases of weighted outerplanar graphs. Information Processing Letters, 2010, 110, 970-974.	0.6	3
15	Immune checkpoint inhibitors for hepatocellular carcinoma – A game changer in treatment landscape. Journal of the Formosan Medical Association, 2022, 121, 1371-1383.	1.7	3
16	Limited Predictive or Prognostic Role of Tumor-Infiltrating Tissue-Resident Memory CD8 T Cells in Patients with Hepatocellular Carcinoma Receiving Immunotherapy. Cancers, 2021, 13, 5142.	3.7	2
17	Perivascular epithelioid cell tumor of the gastrointestinal tract. Journal of Cancer Research and Practice, 2016, 3, 14-18.	0.2	1
18	Minimum Cycle Bases of Weighted Outerplanar Graphs. Lecture Notes in Computer Science, 2009, , 564-572.	1.3	1

#	Article	IF	CITATIONS
19	Abstract 355: CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. , 2010, , .		0
20	Abstract 1636: Increased expression of programmed death-ligand 1 (PD-L1) on infiltrating immune cells of hepatocellular carcinoma (HCC) tissues after sorafenib treatment. , 2017, , .		0
21	Validation of the postneoadjuvant therapy pathological stage of the American Joint Committee on Cancer (AJCC) 8th Edition for predicting outcomes of esophageal squamous cell carcinoma (ESCC) patients receiving neoadjuvant chemoradiotherapy (CRT) followed by esophagectomy Journal of Clinical Oncology. 2018. 36, 138-138.	1.6	0
22	Abstract 3627: Organ-specific differential responses to immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma. , 2018, , .		0